News Author: Jeff Evans Publish date: May 24, 2023
The manufacturer Celltrion is also seeking an interchangeability designation from the FDA, tentatively expected in the fourth quarter of 2024.
News Author: Jeff Evans Publish date: April 12, 2023
Long-term data build on statistically significant improvements demonstrated at 16 weeks across key measures of joint pain, psoriasis, and enthesiti...
News Author: Jeff Evans Publish date: December 16, 2022
Members of the American College of Rheumatology’s Workforce Solutions Committee described a multitude of ways in which the society aims to marshal ...
News Author: Jeff Evans Publish date: November 18, 2022
A randomized trial of therapy to intensively lower urate for patients with gout showed benefits in meeting serum urate goal, tophus size, and decre...
News Author: Jeff Evans Publish date: October 24, 2022
Upadacitinib’s approval for nonradiographic axial spondyloarthritis marks the sixth indication in the United States for the Janus kinase inhibitor....
News Author: Jeff Evans Publish date: October 6, 2022
Researchers show that a majority of the authors of the most recent psoriatic arthritis clinical practice guidelines from the American College of Rh...
News Author: Jeff Evans Publish date: August 17, 2022
The 100-mg/mL version of adalimumab-bwwd (Hadlima) is indicated for the same seven conditions as its 50-mg/mL counterpart.
News Author: Jeff Evans Publish date: August 3, 2022
The approval is based on an extrapolation of data from adult trials in active psoriatic arthritis and adult and pediatric studies in moderate to se...
News Author: Jeff Evans Publish date: July 29, 2022
The number of female prize winners has increased over the past 2 decades to nearly equal that of male winners, but the most prestigious prizes are ...
News Author: Jeff Evans Publish date: June 28, 2022
The Janus kinase inhibitor is already approved for active ankylosing spondylitis in the European Union.
News Author: Jeff Evans Publish date: June 21, 2022
Chronic exposure to particulate matter 2.5 mcm or larger in size at concentrations above 25 mcg per cubic meter raised the likelihood of osteoporos...
News Author: Jeff Evans Publish date: June 8, 2022
Riabni is the second rituximab biosimilar to be approved for rheumatoid arthritis in the United States.
News Author: Jeff Evans Publish date: April 25, 2022
Results from a postmarketing trial conducted solely at U.S. centers found similar, albeit lower, responses to secukinumab 300 mg than was noted in ...
News Author: Jeff Evans Publish date: March 24, 2022
The voluntary recall of Orphenadrine Citrate 100 mg Extended Release Tablets by Sandoz involves 13 lots of the drug that were shipped to consumers ...
News Author: Jeff Evans Publish date: March 16, 2022
Alice Chu, MD, is 1 of 48 people who were charged in 2019 as part of a larger enforcement action involving more than...
